Sufentanil
Discover related
5 sources
How the databases line up — = agree, ≈ partial, ≠ differ. In lists, shared items appear in every source and unique ones in only one (matched case-insensitively).
| PsychonautWiki | TripSit | Pharmacology | DrugCentral | DailyMed | ||
|---|---|---|---|---|---|---|
| Classification | ||||||
| Class / category | — | — | — | ≈ | ||
| Also known as | SufentanilSufentanylSufentaChronogesic | — | — | — | — | |
| Safety | ||||||
| Dangerous interactions | — | — | — | — | ||
| Dose · Intravenous | ||||||
| Threshold | 0.1 μg | — | — | — | — | |
| Light | 1–5 μg | — | — | — | — | |
| Common | 5–10 μg | — | — | — | — | |
| Strong | 10–25 μg | — | — | — | — | |
| Heavy | 25 μg+ | — | — | — | — | |
| Dose · Oral | ||||||
| Light | — | 1–5 µg | — | — | — | |
| Common | — | 5–10 µg | — | — | — | |
| Strong | — | 10–25 µg | — | — | — | |
| Duration | ||||||
| Onset | 1–2 minutes | 1–2 minutes | — | — | — | = |
| Total | — | 5–10 minutes | — | — | — | |
| After-effects | — | 1–12 hours | — | — | — | |
| Pharmacology | ||||||
| Receptor activity | — | — | — | OPRM1OPRD1OPRK1SIGMAR1SLC22A1 | — | |
| Half-life | — | — | The elimination half-life is 164 minutes in adults when administered intravenously (IV). The elimination half-life of sufentanil is shorter (e.g. 97 +/- 42 minutes) in infants and children, and longer in neonates (e.g. 434 +/- 160 minutes) compared to that of adolescents and adults. After a single administration of a 15 microgram sufentanil sublingual tablet, mean terminal phase half-lives in the range of 6-10 hours have been observed. After multiple administrations, a longer average terminal half-life of up to 18 hours was measured, owing to the higher plasma concentrations of sufentanil achieved after repeated dosing and due to the possibility to quantify these concentrations over a longer time period. In adults with normal renal and hepatic function, the plasma half-life in the initial (distribution) phase averages 0.72-1.2 minutes, the plasma half-life in the second (redistribution) phase averages 13.7-17 minutes, and the plasma half-life in the terminal (elimination) phase averages 140-158 minutes. The elimination half-life is longer (434 minutes) in neonates but shorter in infants and children (97 minutes), compared with adults and adolescents. | — | — | |
| Protein binding | — | — | Plasma protein binding of sufentanil, related to the alpha acid glycoprotein concentration, was approximately 93% in healthy males, 91% in mothers and 79% in neonates. | — | — | |
Dose at a glance
Each database's primary-route ladder on one shared scale — see where ranges line up or shift.
Duration at a glance
Total duration on one shared scale.
PsychonautWiki summary
Sufentanil is extraordinarily potent (i.e. active in the micrograms), to the point that the pure powder can result in a fatal overdose if spilled on one's skin. For this reason, it should never be eyeballed. Sufentanil can also be fatal when combined with depressants such as opiates, benzodiazepines, barbiturates, gabapentinoids, thienodiazepines or other GABAergic substances.[1] It is strongly encouraged to wear gloves while handling, use volumetric dosing combined with a milligram scale, and to not consume either moderate or heavy dosages of other depressants in combination with this drug.
TripSit summary
An synthetic analgesic drug that is roughly between 5-10x the potency of it's parent drug, (Fentanyl); It's use is very contained to surgery and post-operative pain.
Fact-sheets from PsychonautWiki. Harm-reduction reference only — not medical advice.